National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced
Sonoma Pharmaceuticals (Nasdaq:SNOA), a healthcare company specializing in Microcyn® technology based stabilized hypochlorous acid (HOCl) products, has received the National Psoriasis Foundation (NPF) Seal of Recognition for its Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel.
The product, which previously earned the National Eczema Association Seal of Acceptance, was independently reviewed by medical experts and met NPF's standards for safety, ingredient quality, and tolerability on sensitive skin. This recognition validates the product's efficacy for people with chronic skin conditions including psoriasis, eczema, and sensitive skin.
Sonoma Pharmaceuticals (Nasdaq:SNOA), azienda sanitaria specializzata nei prodotti a base di acido ipocloroso (HOCl) stabilizzato con tecnologia Microcyn®, ha ottenuto il Sigillo di Riconoscimento della National Psoriasis Foundation (NPF) per il suo Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel.
Il prodotto, già insignito del Sigillo di Accettazione della National Eczema Association, è stato valutato da esperti medici e ha soddisfatto gli standard NPF in termini di sicurezza, qualità degli ingredienti e tollerabilità su pelli sensibili. Questo riconoscimento conferma l'efficacia del prodotto per chi convive con condizioni cutanee croniche come psoriasi, eczema e pelle sensibile.
Sonoma Pharmaceuticals (Nasdaq:SNOA), empresa sanitaria especializada en productos de ácido hipocloroso (HOCl) estabilizado con la tecnología Microcyn®, ha recibido el Sello de Reconocimiento de la National Psoriasis Foundation (NPF) por su Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel.
El producto, que ya obtuvo el Sello de Aceptación de la National Eczema Association, fue revisado por expertos médicos y cumplió con los estándares de la NPF en cuanto a seguridad, calidad de los ingredientes y tolerabilidad en pieles sensibles. Este reconocimiento avala su eficacia para personas con afecciones cutáneas crónicas como psoriasis, eccema y piel sensible.
Sonoma Pharmaceuticals (Nasdaq:SNOA)는 Microcyn® 기술 기반의 안정화된 차아염소산(HOCl) 제품을 전문으로 하는 헬스케어 기업으로, 자사의 Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel이 National Psoriasis Foundation(NPF) 인정 마크을 받았습니다.
이 제품은 이전에 National Eczema Association의 승인 마크를 획득했으며, 의료 전문가들의 독립적 검토를 통해 민감한 피부에서의 안전성, 성분 품질, 내약성 기준을 충족한 것으로 평가되었습니다. 이번 인정은 건선, 습진 및 민감성 피부를 포함한 만성 피부 질환 환자들에게 제품의 효과를 입증합니다.
Sonoma Pharmaceuticals (Nasdaq:SNOA), entreprise de santé spécialisée dans les produits à base d'acide hypochloreux (HOCl) stabilisé grâce à la technologie Microcyn®, a reçu le Sceau de Reconnaissance de la National Psoriasis Foundation (NPF) pour son Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel.
Le produit, déjà titulaire du Sceau d'Acceptation de la National Eczema Association, a été examiné par des experts médicaux indépendants et a respecté les critères de la NPF en matière de sûreté, qualité des ingrédients et tolérabilité sur peau sensible. Cette reconnaissance confirme l'efficacité du produit pour les personnes souffrant d'affections cutanées chroniques telles que le psoriasis, l'eczéma et la peau sensible.
Sonoma Pharmaceuticals (Nasdaq:SNOA), ein Gesundheitsunternehmen, das sich auf mit Microcyn®-Technologie stabilisierte Hypochlorige Säure (HOCl)-Produkte spezialisiert hat, hat das National Psoriasis Foundation (NPF) Seal of Recognition für sein Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel erhalten.
Das Produkt, das bereits das Seal of Acceptance der National Eczema Association erhalten hatte, wurde von medizinischen Experten unabhängig geprüft und erfüllte die NPF-Standards für Sicherheit, Inhaltsstoffqualität und Verträglichkeit auf empfindlicher Haut. Diese Anerkennung bestätigt die Wirksamkeit des Produkts bei chronischen Hauterkrankungen wie Psoriasis, Ekzem und empfindlicher Haut.
- Received prestigious NPF Seal of Recognition for Reliefacyn Advanced
- Product previously earned National Eczema Association Seal of Acceptance
- Independent medical expert verification of product safety and quality
- None.
BOULDER, CO / ACCESS Newswire / August 26, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced that Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel has earned the National Psoriasis Foundation (NPF) Seal of Recognition.
The NPF Seal of Recognition is awarded to products that have been independently reviewed and verified by a panel of medical experts. Products awarded the Seal of Recognition have met the NPF's standards for safety, ingredient quality, and tolerability on sensitive skin.
"We are honored to receive the NPF Seal of Recognition," said Amy Trombly, CEO of Sonoma Pharmaceuticals. "This recognition from the NPF reaffirms the superior efficacy, safety and high standards of our products. We are pleased to offer products like Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel, which has previously received the National Eczema Association Seal of Acceptance, to provide relief to people living with chronic skin conditions like eczema, psoriasis and sensitive skin."
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "opportunities," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
What recognition did Sonoma Pharmaceuticals (SNOA) receive for Reliefacyn Advanced?
What certifications does Sonoma Pharmaceuticals' Reliefacyn Advanced product have?
What conditions can Sonoma Pharmaceuticals' Reliefacyn Advanced treat?
What standards did SNOA's Reliefacyn Advanced meet for the NPF Seal?
